Chancellor Rachel Reeves Aims for Focused Measures on Bills in Upcoming Budget

Treasury head Rachel Reeves has stated she is preparing "specific action to deal with cost of living pressures" in the upcoming financial statement.

Speaking to the BBC, she emphasized that curbing price rises is a collective task of both the government and the central bank.

The UK's price growth is expected to be the highest among the Group of Seven advanced economies this year and the following year.

Potential Utility Cost Interventions

Sources suggest the government could take action to bring down utility costs, for instance by reducing the present 5% rate of value-added tax applied on energy supplies.

A further possibility is to lower some of the government charges presently included in household expenses.

Fiscal Constraints and Expert Predictions

The government will obtain the next draft from the independent fiscal watchdog, the OBR, on the start of the week, which will show how much room there is for such actions.

The expectation from most experts is that Reeves will have to declare higher taxes or expenditure reductions in order to adhere to her voluntary borrowing rules.

Previously on the same day, analysis indicated there was a £22bn deficit for the Treasury chief to fill, which is at the lower end of forecasts.

"There's a joint job between the central bank and the administration to further reduce some of the sources of price increases," the Chancellor informed reporters in Washington, at the annual meetings of the IMF and World Bank.

Revenue Commitments and Global Issues

While a great deal of the focus has been on likely tax increases, the chancellor said the latest data from the OBR had not altered her vow to election pledges not to raise tax levels on earnings tax, VAT or social security contributions.

She attributed an "uncertain global environment" with increasing international and trade issues for the fiscal revenue measures, likely to be focused on those "wealthiest."

International Trade Tensions

Addressing worries about the United Kingdom's economic relations with China she said: "The UK's security interests always come first."

Recent declaration by Chinese authorities to increase trade restrictions on critical minerals and other resources that are key for high-technology production led American leader the US President to suggest an extra 100% import tax on imports from China, raising the prospect of an full-scale commercial conflict between the two largest economies.

The US Treasury Secretary labeled China's decision "economic coercion" and "a international production power grab."

Inquired about considering the US offer to join its dispute with the Asian nation, the Chancellor said she was "extremely troubled" by China's actions and called on the Chinese government "not to put up barriers and restrict access."

She said the action was "harmful for the global economy and causes further challenges."

"It is my opinion there are sectors where we must address China, but there are also significant opportunities to trade with Chinese markets, including financial services and other sectors of the economic system. We've got to get that balance right."

The chancellor also affirmed she was collaborating with G7 counterparts "on our own critical minerals plan, so that we are reduced dependence."

NHS Medicine Pricing and Funding

The Chancellor also acknowledged that the cost the NHS pays for pharmaceuticals could rise as a consequence of current negotiations with the US government and its pharmaceutical firms, in exchange for reduced taxes and investment.

A number of the world's largest pharmaceutical manufacturers have said recently that they are either halting or canceling operations in the UK, with some attributing the insufficient payments they are getting.

Last month, the government science advisor said the price the health service pays for drugs would need to go up to halt businesses and drug research funding leaving the United Kingdom.

Reeves informed the BBC: "We have seen as a result of the pricing regime, that clinical trials, recent pharmaceuticals have not been available in the UK in the extent that they are in other continental states."

"The objective is to guarantee that individuals receiving care from the NHS are able to obtain the top critical drugs in the world. And so we are looking at all of that, and... aiming to secure increased capital into the UK."